In this multinational registry, molecular data on genes other than BCR::ABL1 were determined only for a minority of patients, preventing at present an analysis of their impact in CML-BP outcomes. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.